Compare Intuit Inc. (INTU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Intuit Inc. trades at $303.94 (market cap $79.43B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Intuit Inc. pays a 1.86% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 66 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| INTU | VRTX | |
|---|---|---|
Market Cap | $79.43B | $128.16B |
Volume | 3,518,398 | 806,603 |
Sector | Technology | Health |
52-Week High | $683.39 | $557.96 |
52-Week Low | $255.07 | $407.37 |
Typical Hold Time | 66 Days | 120 Days |
Enterprise Value | $80.65B | $122.29B |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $303.88, up 4.85% today, with strong fundamental performance including 21.3% net income margin and consistent earnings beats. The stock shows bullish technical momentum with resistance at $308 and support at $293. Recent financials reveal robust revenue growth from $18.8B in 2025 to projected $21.4B in 2026, though legal challenges from class action lawsuits present near-term headwinds.
Outlook remains positive with analyst consensus target of $379.68 (25% upside), driven by AI integration and QuickBooks monetization. Key risks include litigation overhang and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, supporting long-term growth trajectory despite technical overbought signals.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
